These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
170 related articles for article (PubMed ID: 25425200)
1. Berberine derivatives reduce atherosclerotic plaque size and vulnerability in apoE(-/-) mice. Chen J; Cao J; Fang L; Liu B; Zhou Q; Sun Y; Wang Y; Li Y; Meng S J Transl Med; 2014 Nov; 12():326. PubMed ID: 25425200 [TBL] [Abstract][Full Text] [Related]
2. Comparative effect of berberine and its derivative 8-cetylberberine on attenuating atherosclerosis in ApoE Feng M; Zou Z; Zhou X; Hu Y; Ma H; Xiao Y; Li X; Ye X Int Immunopharmacol; 2017 Feb; 43():195-202. PubMed ID: 28024280 [TBL] [Abstract][Full Text] [Related]
3. 8,8-Dimethyldihydroberberine with improved bioavailability and oral efficacy on obese and diabetic mouse models. Cheng Z; Chen AF; Wu F; Sheng L; Zhang HK; Gu M; Li YY; Zhang LN; Hu LH; Li JY; Li J Bioorg Med Chem; 2010 Aug; 18(16):5915-24. PubMed ID: 20663675 [TBL] [Abstract][Full Text] [Related]
4. Berberine treatment reduces atherosclerosis by mediating gut microbiota in apoE-/- mice. Shi Y; Hu J; Geng J; Hu T; Wang B; Yan W; Jiang Y; Li J; Liu S Biomed Pharmacother; 2018 Nov; 107():1556-1563. PubMed ID: 30257374 [TBL] [Abstract][Full Text] [Related]
5. The beneficial effects of a direct thrombin inhibitor, dabigatran etexilate, on the development and stability of atherosclerotic lesions in apolipoprotein E-deficient mice : dabigatran etexilate and atherosclerosis. Kadoglou NP; Moustardas P; Katsimpoulas M; Kapelouzou A; Kostomitsopoulos N; Schafer K; Kostakis A; Liapis CD Cardiovasc Drugs Ther; 2012 Oct; 26(5):367-74. PubMed ID: 22940777 [TBL] [Abstract][Full Text] [Related]
6. Berberine and its more biologically available derivative, dihydroberberine, inhibit mitochondrial respiratory complex I: a mechanism for the action of berberine to activate AMP-activated protein kinase and improve insulin action. Turner N; Li JY; Gosby A; To SW; Cheng Z; Miyoshi H; Taketo MM; Cooney GJ; Kraegen EW; James DE; Hu LH; Li J; Ye JM Diabetes; 2008 May; 57(5):1414-8. PubMed ID: 18285556 [TBL] [Abstract][Full Text] [Related]
7. EphA2 knockdown attenuates atherosclerotic lesion development in ApoE(-/-) mice. Jiang H; Li X; Zhang X; Liu Y; Huang S; Wang X Cardiovasc Pathol; 2014; 23(3):169-74. PubMed ID: 24561077 [TBL] [Abstract][Full Text] [Related]
8. Transglutaminase 2 deficiency decreases plaque fibrosis and increases plaque inflammation in apolipoprotein-E-deficient mice. Van Herck JL; Schrijvers DM; De Meyer GR; Martinet W; Van Hove CE; Bult H; Vrints CJ; Herman AG J Vasc Res; 2010; 47(3):231-40. PubMed ID: 19893320 [TBL] [Abstract][Full Text] [Related]
9. Berberine activates peroxisome proliferator-activated receptor gamma to increase atherosclerotic plaque stability in Apoe Li H; He C; Wang J; Li X; Yang Z; Sun X; Fang L; Liu N J Diabetes Investig; 2016 Nov; 7(6):824-832. PubMed ID: 27181586 [TBL] [Abstract][Full Text] [Related]
10. Berberine attenuates atherosclerotic lesions and hepatic steatosis in ApoE Ma CY; Shi XY; Wu YR; Zhang Y; Yao YH; Qu HL; Zhang W; Guo YL; Xu RX; Li JJ Ann Transl Med; 2021 Oct; 9(20):1517. PubMed ID: 34790723 [TBL] [Abstract][Full Text] [Related]
11. Chronic administration of mitochondrion-targeted peptide SS-31 prevents atherosclerotic development in ApoE knockout mice fed Western diet. Zhang M; Zhao H; Cai J; Li H; Wu Q; Qiao T; Li K PLoS One; 2017; 12(9):e0185688. PubMed ID: 28961281 [TBL] [Abstract][Full Text] [Related]
12. Poly(ADP-ribose) polymerase inhibition reduces atherosclerotic plaque size and promotes factors of plaque stability in apolipoprotein E-deficient mice: effects on macrophage recruitment, nuclear factor-kappaB nuclear translocation, and foam cell death. Oumouna-Benachour K; Hans CP; Suzuki Y; Naura A; Datta R; Belmadani S; Fallon K; Woods C; Boulares AH Circulation; 2007 May; 115(18):2442-50. PubMed ID: 17438151 [TBL] [Abstract][Full Text] [Related]
13. [Impact of rosuvastatin on atherosclerosis lesions in apolipoprotein E knockout mice]. Luo RN; Tao LJ; Zhou J; Wang R; Lu MM; Fu X Zhonghua Xin Xue Guan Bing Za Zhi; 2011 Aug; 39(8):743-8. PubMed ID: 22169423 [TBL] [Abstract][Full Text] [Related]
14. Transgenic Overexpression of IL-37 Protects Against Atherosclerosis and Strengthens Plaque Stability. Liu J; Lin J; He S; Wu C; Wang B; Liu J; Duan Y; Liu T; Shan S; Yang K; Dong N; Ji Q; Huang K; Li D Cell Physiol Biochem; 2018; 45(3):1034-1050. PubMed ID: 29439249 [TBL] [Abstract][Full Text] [Related]
16. Transforming berberine into its intestine-absorbable form by the gut microbiota. Feng R; Shou JW; Zhao ZX; He CY; Ma C; Huang M; Fu J; Tan XS; Li XY; Wen BY; Chen X; Yang XY; Ren G; Lin Y; Chen Y; You XF; Wang Y; Jiang JD Sci Rep; 2015 Jul; 5():12155. PubMed ID: 26174047 [TBL] [Abstract][Full Text] [Related]
17. Advanced glycation end-product Nε-carboxymethyl-Lysine accelerates progression of atherosclerotic calcification in diabetes. Wang Z; Jiang Y; Liu N; Ren L; Zhu Y; An Y; Chen D Atherosclerosis; 2012 Apr; 221(2):387-96. PubMed ID: 22305260 [TBL] [Abstract][Full Text] [Related]
18. IL-9 aggravates the development of atherosclerosis in ApoE-/- mice. Zhang W; Tang T; Nie D; Wen S; Jia C; Zhu Z; Xia N; Nie S; Zhou S; Jiao J; Dong W; Lv B; Xu T; Sun B; Lu Y; Li Y; Cheng L; Liao Y; Cheng X Cardiovasc Res; 2015 Jun; 106(3):453-64. PubMed ID: 25784693 [TBL] [Abstract][Full Text] [Related]
19. Suppressive effects of berberine on atherosclerosis via downregulating visfatin expression and attenuating visfatin-induced endothelial dysfunction. Wan Q; Liu Z; Yang Y; Cui X Int J Mol Med; 2018 Apr; 41(4):1939-1948. PubMed ID: 29393413 [TBL] [Abstract][Full Text] [Related]
20. Suxiaojiuxin pill enhances atherosclerotic plaque stability by modulating the MMPs/TIMPs balance in ApoE-deficient mice. Zhang J; Zhuang P; Lu Z; Zhang M; Zhang T; Zhang Y; Wang J; Liu D; Tong Y J Cardiovasc Pharmacol; 2014 Aug; 64(2):120-6. PubMed ID: 24621651 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]